The ADRIATIC study: revolutionizing the standard treatment paradigm for concurrent chemoradiotherapy in limited-stage small cell lung cancer

Small cell lung cancer (SCLC) constitutes approximately 15 % of all lung cancer cases, characterized by rapid tumor growth, a high proliferation rate, and a propensity for early metastasis. 1 Approximately one-third of SCLC patients are diagnosed at the limited-stage.Historically, the standard of care for these patients has been 4-6 cycles of concurrent chemoradiotherapy (cCRT), with the exception of a minority of early-stage T1-2N0 patients who may undergo radical surgery. 2 Despite an initial high sensitivity to treatment, over 50 % of patients experience disease recurrence within two years, with a median overall survival (OS) ranging from 16 to 24 months.For the past three decades, while there have been novel explorations in radiotherapy dosing and fractionation, the treatment paradigm for limited-stage SCLC (LS-SCLC) has remained largely unchanged, with no significant improvement in patient survival outcomes.The PACIFIC study established the efficacy and safety of sequential durvalumab consolidation therapy post-cCRT in stage III locally advanced, unresectable non-small cell lung cancer (NSCLC). 3 , 4 This study suggested that a sequential immunotherapy approach following cCRT might make a relatively highly responsive immune microenvironment, eliminate potential micrometastases, and extend disease-free survival (DFS).However, current guidelines lack clear recommendations for consolidation therapy following cCRT in LS-SCLC patients.On September 13th of this year, Professor Ying Cheng unveiled the first interim results from the ADRIATIC study in the New England Journal of Medicine . 5 This groundbreaking study demonstrated, for the first time, that maintenance therapy with durvalumab following cCRT significantly improves progression-free survival (PFS) and OS in LS-SCLC patients.The ADRIATIC study is a randomized, double-blind, global, multicenter, phase III clinical trial investigating the efficacy and safety of durvalumab, placebo, or durvalumab in combination with tremelimumab, as consolidation therapy (up to two years) for LS-SCLC patients without disease progression after concurrent platinum-based chemoradiotherapy.The primary endpoints were OS and PFS for durvalumab versus placebo, with secondary endpoints being OS and PFS for the combination therapy versus placebo.The study enrolled 730 patients, with 264 in the durvalumab group and 266 in the placebo group.The primary interim data for these two groups have been Comment on: